This application is Part B of a competing renewal to the Pittsburgh component of the Multicenter AIDS Cohort Study (MACS) Cooperative Agreement (1 U01 AI035041), the companion to the Part A composite application that is being submitted by CAMACS. The MACS began in 1983 as a longitudinal study of the natural history of AIDS in men who have sex with men (MSM). This request is for an additional five years of support for clinical follow-up and laboratory testing of the cohort of MSM in the Pittsburgh MACS. The broad objectives of the Pittsburgh MACS are to fulfill the specific aims of the Part A master MACS application, and do special studies locally in Pittsburgh to enhance our epidemiologic and pathogenesis knowledge in relation to treatment intervention, and development of immunotherapeutic and prophylactic vaccines.
Our specific aims are to determine the long-term natural and treated history of HIV infection in MSM, characterize the responses to HIV therapy, including psychological and behavioral predictors, examine the effects of HIV and prolonged HIV therapy exposure on lipodystrophy, diabetes, cardiovascular disease, liver disease, malignancies, neurocognitive function, substance use, kidney disease, and other outcomes, assess the effects of aging on the clinical course of HIV and HIV therapy, examine the interaction between host genetics and HIV, define HIV pathogenesis, characterize HIV-associated cancers including identification of risk factors, determine socio-behavioral factors that affect HIV transmission and disease progression, characterize concomitant infections and their effects on HIV disease progression, examine the effects of substance abuse on antiretroviral treatment effectiveness, maintain longitudinally collected epidemiological data and biological specimen repository as a platform to facilitate natural history and pathogenesis studies, perform clinical and lab testing of MSM in the Pittsburgh MACS, including T-cell subsets, anti-HIV Ab, HIV viral load, hepatitis B virus and hepatitis C virus testing, serum lipid/insulin/glucose levels, liver function tests, renal function and cardiovascular studies. This research has direct relevance to the mission of the NIH to cure and prevent HIV infection and AIDS.

Public Health Relevance

As part of the MACS research consortium, the Pittsburgh MACS proposes to continue its 25 year scientific investigation into the natural history of HIV/AIDS. This research provides insight into the mechanisms of HIV infection, the effects of HIV therapy, and development of therapeutic and preventative vaccines for HIV infection. It is highly relevant to HIV/AIDS public health programs of the NIH.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI035041-18S2
Application #
8145356
Study Section
Special Emphasis Panel (ZAI1-EB-A (J1))
Program Officer
Roe, Joanad'Arc C
Project Start
2010-09-30
Project End
2012-09-29
Budget Start
2010-09-30
Budget End
2012-09-29
Support Year
18
Fiscal Year
2010
Total Cost
$415,530
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Public Health
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Mellor-Crummey, Lauren E; Lake, Jordan E; Wilhalme, Holly et al. (2018) A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. J Clin Gastroenterol Hepatol 2:
Adland, Emily; Hill, Matilda; Lavandier, Nora et al. (2018) Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J Virol 92:
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Irwin, Michael R; Archer, Gemma; Olmstead, Richard et al. (2018) Increased risk of depression in non-depressed HIV infected men with sleep disturbance: Prospective findings from the Multicenter AIDS Cohort Study. EBioMedicine 36:454-460
Guha, Debjani; Wagner, Marc C E; Ayyavoo, Velpandi (2018) Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. J Neuroinflammation 15:126
Li, Yijia; Nouraie, Seyed Mehdi; Kessinger, Cathy et al. (2018) Factors Associated With Progression of Lung Function Abnormalities in HIV-Infected Individuals. J Acquir Immune Defic Syndr 79:501-509
Tipton, Laura; Cuenco, Karen T; Huang, Laurence et al. (2018) Measuring associations between the microbiota and repeated measures of continuous clinical variables using a lasso-penalized generalized linear mixed model. BioData Min 11:12
Viana, I F T; Coêlho, D F; Palma, M L et al. (2018) Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection. Epidemiol Infect 146:1293-1300

Showing the most recent 10 out of 552 publications